Thuillier Y, Lubetzki C, Goujet-Zalc C, Galli A, Lhermitte F, Zalc B
Laboratoire de Biochimie, INSERM U. 134, Paris, France.
J Neurochem. 1988 Aug;51(2):380-4. doi: 10.1111/j.1471-4159.1988.tb01049.x.
An enzyme-linked immunosorbent assay (ELISA) to determine the level of galactosylceramide (GalC) in biological fluids is described. The assay uses GalC-coated plastic microtiter plates, with binding of an antibody to GalC detected by a peroxidase-labeled second antibody. The GalC level was directly estimated in the biological samples, without prior extraction, by competition with the coated hapten. This method allows the detection of 62 pmol of GalC (1.2 nmol/ml). Results using this procedure revealed positive sera only among patients suffering a myelin-destructive process: either primary, as in multiple sclerosis, or secondary to brain damage, as during ischemic strokes.
本文描述了一种用于测定生物体液中半乳糖神经酰胺（GalC）水平的酶联免疫吸附测定（ELISA）方法。该测定使用包被有GalC的塑料微量滴定板，通过过氧化物酶标记的二抗检测抗体与GalC的结合。通过与包被的半抗原竞争，无需预先提取即可直接估算生物样品中的GalC水平。该方法能够检测到62皮摩尔的GalC（1.2纳摩尔/毫升）。使用该方法得到的结果显示，仅在患有髓鞘破坏过程的患者血清中呈阳性：要么是原发性的，如在多发性硬化症中；要么是继发于脑损伤的，如在缺血性中风期间。
